<DOC>
	<DOC>NCT01104753</DOC>
	<brief_summary>Confirmation of safety profile of Pentasa slow release tablets 500 mg in patients with ulcerative colitis (UC).</brief_summary>
	<brief_title>A Study of Pentasa in Patients With Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Patients suffering from ulcerative colitis Hypersensitivity to mesalazine, salicylates or to any excipient Severe damage to liver or renal functions</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>